MS patients belonged to four clinical subtypes (53 RR, 58 SP, 19 PP, and 16 CIS), and were treated in 70% of cases with various therapies (59 with interferon beta-1, 30 with natalizumab, 8 with glatiramer acetate, 3 with fingolimod, 1 with azathioprine, and 1 with mitoxantrone). This evidence concerns the gene IFNB1 and in situ carcinoma.